A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent